HMGCS2 and clear cell renal carcinoma: Aberrant expression of HMGCS2 in pan-cancer is closely associated with clinical pathology and tumor tissue, suggesting its potential as a therapeutic target for cancer suppression, particularly in clear cell renal cell carcinoma.